AK006 OLE in Chronic Spontaneous Urticaria

Phase 1, open-label, single-arm trial of AK006 in chronic spontaneous urticaria (CSU), sponsored by Allakos Inc. Primary endpoints: Incidence of adverse events (AEs), treatment-emergent adverse events, serious adverse events, adverse events of special interest, AEs leading to discontinuation at 30 weeks and Incidence of clinically significant abnormal laboratory values, ECGs, and vital signs at 30 weeks. Started Aug 2024; status: completed.